Sanofi Collaborates with Aetion to Leverage its Evidence Platform for Advancing Regulatory Submissions

 Sanofi Collaborates with Aetion to Leverage its Evidence Platform for Advancing Regulatory Submissions

Sanofi Collaborates with Aetion to Leverage its Evidence Platform for Advancing Regulatory Submissions

Shots:

  • Sanofi is launching an enterprise-wide project to assimilate its real-world data platform, DARWIN with the Aetion’s Evidence Platform for advancing the efficient use of real-world evidence to facilitate regulatory-grade studies with deep transparency while opening access to new real-world data
  • The collaboration will lead to the transformation of the health care ecosystem following the FDA’s prioritizing efforts to incorporate RWE as a companion to clinical studies data, aiding in regulatory decision making. The US FDA intends to release its draft RWE guidance before the end of 2020
  • Sanofi’s Darwin is designed to compile and analyze de-identified data, while the Aetion’s Evidence platform analyzes real-world data to expose answers about the effectiveness, safety and value of drugs

Click here to­ read full press release/ article | Ref: Sanofi | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post